海尔生物：自上市以来公司已连续6年实施分红，累计分红7.88亿元

Core Viewpoint - Haier Biomedical is committed to aligning management interests with company development and shareholder value, establishing a compensation system that matches market development, operational performance, and sustainable growth [1] Summary by Relevant Sections Management Compensation - The company has developed a management compensation system that is compatible with market development and aligns with both company performance and individual achievements [1] Investor Returns - Haier Biomedical has implemented continuous dividends for six consecutive years since its listing, with a total dividend payout of 788 million RMB. The dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted action parties have increased their holdings in the company three times, with a total investment of approximately 384 million RMB [1] - The company has initiated three rounds of share repurchase plans, with a total repurchase amount of about 250 million RMB, and has canceled 1.4596 million shares from the repurchased stock on January 6, 2026 [1] Regulatory Compliance - The company emphasizes regulatory operations and diligently fulfills its information disclosure obligations, stating that there is currently no undisclosed information [1]